$NBIX
AI AnalysisGenerated on May 11, 2026
AI Score
Hold$NBIX
Neurocrine Biosciences
$NBIXNASDAQHealthcareLarge-Cap
Neurocrine develops treatments for neurological and endocrine disorders including Ingrezza for tardive dyskinesia.
Market Cap
$14.0B
Revenue (TTM)
$2.2B
+18.0%
Net Income (TTM)
$0.5B
+25.0%
EPS (TTM)
$3.60
P/E Ratio
38.0
Dividend Yield
0.0%
52-Week Range
$105-$155
Beta
0.42
Dimension Scores
Fundamental
72Technical
70Sentiment
76Risk / Reward
72Momentum
74Financial Health
Profitability
77strong
Growth
77strong
Liquidity
80strong
Solvency
74strong
Efficiency
70strong
Valuation, technical analysis, investment thesis, risk assessment and more for $NBIX
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.